|
1
|
Travis WD, Brambilla E and
Muller-Hermelink HK: World Health Organization Classification of
Tumours, Pathology and Genetics: Tumours of the Lung, Pleura,
Thymus and Heart. IARC Press; Lyon: 2004
|
|
2
|
Laird AD and Cherrington JM: Small
molecule tyrosine kinase inhibitors: clinical development of
anticancer agents. Expert Opin Investig Drugs. 12:51–64. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maulik G, Kijima T and Salgia R: Role of
receptor tyrosine kinases in lung cancer. Methods Mol Med.
74:113–125. 2003.PubMed/NCBI
|
|
4
|
Lamorte L and Park M: The receptor
tyrosine kinases: role in cancer progression. Surg Oncol Clin N Am.
10:271–288. 2001.PubMed/NCBI
|
|
5
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003.
|
|
6
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy of gefitinib, an inhibitor of the epidermal growth factor
receptor tyrosine kinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naldini L, Weidner KM, Vigna E, et al:
Scatter factor and hepatocyte growth factor are indistinguishable
ligands for the MET receptor. EMBO J. 10:2867–2878. 1991.PubMed/NCBI
|
|
10
|
Bottaro DP, Rubin JS, Faletto DL, et al:
Identification of the hepatocyte growth factor receptor as the
c-met proto-oncogene product. Science. 251:802–804. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maulik G, Shrikhande A, Kijima T, Ma PC,
Morrison PT and Salgia R: Role of the hepatocyte growth factor
receptor, c-Met, in oncogenesis and potential for therapeutic
inhibition. Cytokine Growth Factor Rev. 13:41–59. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cooper CS, Park M, Blair DG, et al:
Molecular cloning of a new transforming gene from a chemically
transformed human cell line. Nature. 311:29–33. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen JT, Lin TS, Chow KC, et al: Cigarette
smoking induces overexpression of hepatocyte growth factor in type
II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol.
34:264–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura Y, Niki T, Goto A, et al: c-Met
activation in lung adenocarcinoma tissues: an immunohistochemical
analysis. Cancer Sci. 98:1006–1013. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsao MS, Liu N, Chen JR, et al:
Differential expression of Met/hepatocyte growth factor receptor in
subtypes of non-small cell lung cancers. Lung Cancer. 20:1–16.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beau-Faller M, Gaub MP, Schneider A, et
al: Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF
candidate genes in non-small cell lung cancer sub-types,
implication for progression. Eur J Cancer. 39:2538–2547. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smolen GA, Sordella R, Muir B, et al:
Amplification of MET may identify a subset of cancers with extreme
sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
Proc Natl Acad Sci USA. 103:2316–2321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miller CT, Lin L, Casper AM, et al:
Genomic amplification of MET with boundaries within fragile site
FRA7G and upregulation of MET pathways in esophageal
adenocarcinoma. Oncogene. 25:409–418. 2006.PubMed/NCBI
|
|
20
|
Que J, Luo X, Schwartz RJ and Hogan BL:
Multiple roles for Sox2 in the developing and adult mouse trachea.
Development. 136:1899–1907. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gontan C, de Munck A, Vermeij M, Grosveld
F, Tibboel D and Rottier R: Sox2 is important for two crucial
processes in lung development: branching morphogenesis and
epithelial cell differentiation. Dev Biol. 317:296–309. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park KS, Wells JM, Zorn AM, et al:
Transdifferentiation of ciliated cells during repair of the
respiratory epithelium. Am J Respir Cell Mol Biol. 34:151–157.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsukamoto T, Mizoshita T, Mihara M, et al:
Sox2 expression in human stomach adenocarcinomas with gastric and
gastric-and-intestinal-mixed phenotypes. Histopathology.
46:649–658. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li XL, Eishi Y, Bai YQ, et al: Expression
of the SRY-related HMG box protein SOX2 in human gastric carcinoma.
Int J Oncol. 24:257–263. 2004.PubMed/NCBI
|
|
25
|
Hussenet T, Dali S, Exinger J, et al: SOX2
is an oncogene activated by recurrent 3q26.3 amplifications in
human lung squamous cell carcinomas. PLoS One. 5:e89602010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ebright MI, Zakowski MF, Martin J, et al:
Clinical pattern and pathologic stage but not histologic features
predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg.
74:1640–1647. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ, Flood SJ, Marmaro J, Giusti W
and Deetz K: Oligonucleotides with fluorescent dyes at opposite
ends provide a quenched probe system useful for detecting PCR
product and nucleic acid hybridization. PCR Methods Appl.
4:357–362. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Higuchi R, Fockler C, Dollinger G and
Watson R: Kinetic PCR analysis: real-time monitoring of DNA
amplification reactions. Biotechnology (NY). 11:1026–1030. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Holland PM, Abramson RD, Watson R and
Gelfand DH: Detection of specific polymerase chain reaction product
by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus
DNA polymerase. Proc Natl Acad Sci USA. 88:7276–7280. 1991.
|
|
30
|
Bieche I, Olivi M, Champeme MH, Vidaud D,
Lidereau R and Vidaud M: Novel approach to quantitative polymerase
chain reaction using real-time detection: application to the
detection of gene amplification in breast cancer. Int J Cancer.
78:661–666. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Beau-Faller M, Ruppert AM, Voegeli AC, et
al: MET gene copy number in non-small cell lung cancer: molecular
analysis in a targeted tyrosine kinase inhibitor naive cohort. J
Thorac Oncol. 3:331–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Turke AB, Zejnullahu K, Wu YL, et al:
Preexistence and clonal selection of MET amplification in EGFR
mutant NSCLC. Cancer Cell. 17:77–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maestrini E, Tamagnone L, Longati P, et
al: A family of transmembrane proteins with homology to the
MET-hepatocyte growth factor receptor. Proc Natl Acad Sci USA.
93:674–678. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Comoglio PM and Boccaccio C: The HGF
receptor family: unconventional signal transducers for invasive
cell growth. Genes Cells. 1:347–354. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
De Herdt MJ and Baatenburg de Jong RJ: HGF
and c-MET as potential orchestrators of invasive growth in head and
neck squamous cell carcinoma. Front Biosci. 13:2516–2526.
2008.PubMed/NCBI
|
|
36
|
Go H, Jeon YK, Park HJ, Sung SW, Seo JW
and Chung DH: High MET gene copy number leads to shorter survival
in patients with non-small cell lung cancer. J Thorac Oncol.
5:305–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Okuda K, Sasaki H, Yukiue H, Yano M and
Fujii Y: Met gene copy number predicts the prognosis for completely
resected non-small cell lung cancer. Cancer Sci. 99:2280–2285.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bean J, Brennan C, Shih JY, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cappuzzo F, Marchetti A, Skokan M, et al:
Increased MET gene copy number negatively affects survival of
surgically resected non-small-cell lung cancer patients. J Clin
Oncol. 27:1667–1674. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Masui S, Nakatake Y, Toyooka Y, et al:
Pluripotency governed by Sox2 via regulation of Oct3/4 expression
in mouse embryonic stem cells. Nat Cell Biol. 9:625–635. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wicha MS, Liu S and Dontu G: Cancer stem
cells: an old idea--a paradigm shift. Cancer Res. 66:1883–1890.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ben-Porath I, Thomson MW, Carey VJ, et al:
An embryonic stem cell-like gene expression signature in poorly
differentiated aggressive human tumors. Nat Genet. 40:499–507.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen Y, Shi L, Zhang L, et al: The
molecular mechanism governing the oncogenic potential of SOX2 in
breast cancer. J Biol Chem. 283:17969–17978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Biermann K, Heukamp LC, Steger K, et al:
Genome-wide expression profiling reveals new insights into
pathogenesis and progression of testicular germ cell tumors. Cancer
Genomics Proteomics. 4:359–367. 2007.PubMed/NCBI
|
|
45
|
Sholl LM, Long KB and Hornick JL: Sox2
expression in pulmonary non-small cell and neuroendocrine
carcinomas. Applied immunohistochemistry & molecular
morphology: AIMM/official publication of the Society for Applied
Immunohistochemistry. 18:55–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hussenet T and du Manoir S: SOX2 in
squamous cell carcinoma: amplifying a pleiotropic oncogene along
carcinogenesis. Cell Cycle. 9:1480–1486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bass AJ, Watanabe H, Mermel CH, et al:
SOX2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bjorkqvist AM, Husgafvel-Pursiainen K,
Anttila S, et al: DNA gains in 3q occur frequently in squamous cell
carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes
Cancer. 22:79–82. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sholl LM, Barletta JA, Yeap BY, Chirieac
LR and Hornick JL: Sox2 protein expression is an independent poor
prognostic indicator in stage I lung adenocarcinoma. Am J Surg
Pathol. 34:1193–1198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
McCaughan F, Pole JC, Bankier AT, et al:
Progressive 3q amplification consistently targets SOX2 in
preinvasive squamous lung cancer. Am J Respir Crit Care Med.
182:83–91. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bastide K, Ugolin N, Levalois C, Bernaudin
JF and Chevillard S: Are adenosquamous lung carcinomas a simple mix
of adenocarcinomas and squamous cell carcinomas, or more complex at
the molecular level? Lung Cancer. 68:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
